We are live on
!
Find out more
FA
Fagan Associates Portfolio holdings
AUM
$813M
1-Year Est. Return
37.92%
This Fund
S&P 500
This Quarter
Est. Return
+4.34%
1 Year Est. Return
+37.92%
3 Year Est. Return
+110.01%
5 Year Est. Return
+134.08%
10 Year Est. Return
+676.44%
AUM
$246M
AUM Growth
+$12.4M
(+5.3%)
Cap. Flow
+$4M
Cap. Flow
% of AUM
1.62%
Top 10 Holdings %
Top 10 Hldgs %
38.42%
Holding
118
New
7
Increased
68
Reduced
27
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$1.81M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$750K |
| 3 |
Walt Disney
DIS
|
+$475K |
| 4 |
Boston Scientific
BSX
|
+$362K |
| 5 |
Equinix
EQIX
|
+$353K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$2.26M |
| 2 |
Take-Two Interactive
TTWO
|
+$1.95M |
| 3 |
The Mosaic Company
MOS
|
+$802K |
| 4 |
NEWR
New Relic, Inc.
NEWR
|
+$528K |
| 5 |
Fluor
FLR
|
+$210K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.3% |
| 2 | Financials | 16.78% |
| 3 | Communication Services | 11.51% |
| 4 | Consumer Discretionary | 11.12% |
| 5 | Industrials | 8.15% |
Similar funds
KCP
ACM
BCM
RIM
CCM
VT
UM
IAM
Fagan Associates's Q2 2019 Portfolio in Review
As of Q2 2019, Fagan Associates held 118 positions worth $246M, up 5.3% from $234M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Fagan Associates's Q2 2019 filing shows 7 new, 68 increased, 27 reduced and 6 closed positions. Its largest new stake was Advanced Micro Devices: 63,470 shares worth $1.93M. The largest sale was Regeneron Pharmaceuticals, an estimated $2.26M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 18% a quarter earlier, followed by Financials and Communication Services.
- Fagan Associates's largest Q2 2019 buy was Advanced Micro Devices: 63,470 shares worth $1.93M.
- Fagan Associates added most to Walt Disney in Q2 2019, an estimated $475K increase.
- Fagan Associates's biggest Q2 2019 reduction was Intel, cutting an estimated $64.4K.
- Fagan Associates fully exited Regeneron Pharmaceuticals in Q2 2019, selling an estimated $2.26M.
- Fagan Associates's ten largest holdings make up 38% of its $246M portfolio in Q2 2019.
- Fagan Associates opened 7 new positions and closed 6 in Q2 2019.
- Fagan Associates's portfolio value rose 5.3% quarter-over-quarter to $246M.
Based on Fagan Associates's 13F filing for Q2 2019, filed 12 Jul 2019.